Does urinary peptide content differ between COPD patients with and without inherited alpha-1 antitrypsin deficiency?

Area of Science:

• Biochemistry
• Proteomics
• Pulmonology

Background:

• Differentiating alpha-1 antitrypsin (A1AT) genetic variants (PiMM vs. PiZZ) in COPD is crucial for understanding disease and personalizing treatment.
• Urinary peptides may serve as biomarkers for A1AT-related COPD phenotypes.

Purpose of the Study:

• To investigate if urinary peptides can distinguish between COPD patients with normal (PiMM) and deficient (PiZZ) A1AT genotypes.
• To identify specific urinary peptides associated with A1AT deficiency in COPD.

Main Methods:

• Analysis of urine samples from 19 stable COPD patients (7 PiMM, 12 PiZZ) using capillary electrophoresis coupled to mass spectrometry (CE-MS).
• Identification and quantification of differentially expressed peptides between the PiMM and PiZZ groups.

Main Results:

• 66 unique peptides (from 36 proteins) differed significantly between PiZZ and PiMM COPD patients.
• Collagen peptides (COL1A1, COL5A3) were abundant and could differentiate genotypes with high sensitivity and specificity.
• PiZZ patients showed lower levels of peptides related to lipid and retinoic acid metabolism, and higher levels of peptides from MDS1, EVII, gelsolin, and hemoglobin alpha.

Conclusions:

• Urinary peptide profiles differ between COPD patients with PiMM and PiZZ A1AT genotypes.
• Specific urinary peptides, particularly collagen fragments, show potential as biomarkers for A1AT-related COPD phenotypes.
• These findings support the use of urinary peptidomics for personalized COPD management based on A1AT status.